Trinidad and Tobago

Reimbursed Care Access

Trinidad and Tobago classifies most classical psychedelics (psilocybin, DMT, mescaline, MDMA, 2C-X, 5‑MeO‑DMT, etc.) as controlled/“dangerous” substances under the Dangerous Drugs Act, with no routine medical reimbursement pathways; ketamine is available and listed for clinical (anaesthetic) use in the national formulary, and may be used off‑label in private care for mood disorders but without an established, publicly reimbursed esketamine program. Clinical research access is limited and tightly regulated under national law.